Skip to content

Survey Study for Pain Management, Wound Care, Scar Care or UDT

Survey of Patients Who Have Been Prescribed a Topical Compound for Pain Management, Wound Care or Scar Care or to Patients Who Have Been Requested to do a Urinary Drug Test (UDT) by Their Provider.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02195063
Enrollment
10000
Registered
2014-07-21
Start date
2013-11-30
Completion date
Unknown
Last updated
2015-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Scars, Urinary Drug Testing, Wounds

Keywords

Pain management, Scar care, Wound care, UDT, Urinary drug testing

Brief summary

This is a survey study that will be given to patients who have been prescribed a topical compound for pain management, wound care or scar care or to patients who have been requested to do a urinary drug test (UDT) by their provider. The initial survey for pain management, wound care, scar care or UDT will be given to the patient by their providers during their office visit.

Detailed description

We have designed a survey study that will be given to patients who have been prescribed a topical compound for pain management, wound care or scar care or to patients who have been requested to do a urinary drug test (UDT) by their provider. The initial survey for pain management, wound care, scar care or UDT will be given to the patient by their providers during their office visit. Follow-up surveys will be given at 30, 60, and 90 days. These surveys will be collected by e-mail or follow-up calls from Datum Research, LLC, contract research organization. Data collection for this study will be derived through the 4 patient surveys (initial, 30 day, 60 day, and 90 day) and the prescription written by the provider. The survey study will enroll patients until December 31, 2014, or until sufficient numbers have been achieved. Rahm Foundation will continue the study until: * Sufficient information has accumulated to meet the scientific objectives of the Study (i.e. numeric targets or effect size) * The feasibility of collecting sufficient information diminishes to unacceptable levels, poor enrollment, loss to follow-up and/or * Other methods of gathering appropriate information become achievable or are deemed preferable. Datum Research will need to have access to the prescription to see what compound was prescribed.

Interventions

None listed

Sponsors

Datum Research, LLC
CollaboratorUNKNOWN
Rahm Foundation
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Prescribed a topical cream for pain, scar care, or wound OR Provider preforms urinary drug test

Exclusion criteria

* Subjects with legally authorized representatives * Minors * Prisoners

Design outcomes

Primary

MeasureTime frameDescription
Change in UDT survey results from baseline at 90 daysbaseline and 90 daysSurvey on urinary drug testing
Change in pain survey results from baseline at 30 daysbaseline and 30 daysSurvey on pain management
Change in pain survey results from baseline at 60 daysbaseline and 60 daysSurvey on pain management
Change in pain survey results from baseline at 90 daysbaseline and 90 daysSurvey on pain management
Change in scar care survey results from baseline at 30 daysbaseline and 30 daysSurvey on scar care
Change in scar care survey results from baseline at 60 daysbaseline and 60 daysSurvey on scar care
Change in scar care survey results from baseline at 90 daysbaseline and 90 daysSurvey on scar care
Change in wound care survey results from baseline at 30 daysbaseline and 30 daysSurvey on wound care
Change in wound care survey results from baseline at 60 daysbaseline and 60 daysSurvey on wound care
Change in wound care survey results from baseline at 90 daysbaseline and 90 daysSurvey on wound care
Change in UDT survey results from baseline at 30 daysbaseline and 30 daysSurvey on urinary drug testing
Change in UDT survey results from baseline at 60 daysbaseline and 60 daysSurvey on urinary drug testing

Secondary

MeasureTime frameDescription
Change in pain survey results from 30 days at 60 days30 days and 60 daysSurvey on pain management
Change in pain survey results from 30 days at 90 days30 days and 90 daysSurvey on pain management
Change in pain survey results from 60 days at 90 days60 days and 90 daysSurvey on pain management
Length of hospital stayat baselineif applicable
Change in scar care survey results from 30 days at 60 days30 days and 60 daysSurvey on scar care
Change in scar care survey results from 30 days at 90 days30 days and 90 daysSurvey on scar care
Change in scar care survey results from 60 days at 90 days60 days and 90 daysSurvey on scar care
Change in wound care survey results from 30 days at 60 days30 days and 60 daysSurvey on wound care
Change in wound care survey results from 30 days at 90 days30 days and 90 daysSurvey on wound care
Change in UDT survey results from 60 days at 90 days60 days and 90 daysSurvey on urinary drug testing
Change in UDT survey results from 30 days at 60 days30 days and 60 daysSurvey on urinary drug testing
Change in UDT survey results from 30 days at 90 days30 days and 90 daysSurvey on urinary drug testing

Countries

United States

Contacts

Primary ContactChristina R Cook, PhD
ccook@blueprintpathways.com615-712-9574
Backup ContactRisa Tyo, PharmD
rtyo@datumcro.com615-712-9574

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026